Thaer Idrees, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1295122745
Payments from drug & device makers
What this record shows
Boehringer Ingelheim International GmbH accounts for 83.1% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in GA, where the typical reported total is $2,873.
Across 15 payments — averaging $99.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Boehringer Ingelheim$150
- Corcept Therapeutics$104
Across 17 payments — averaging $29,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$496K
- Amgen$7K
What the payments were for
- Travel & lodging$74950%
- Food & beverage$74950%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 12 | $1,244 |
| Boehringer Ingelheim | 2 | $150 |
| Corcept Therapeutics | 1 | $104 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$104
How this compares
$1,497 in reported general payments places this provider in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 358 | $385,635 |
| TrulicityDulaglutide | 157 | $188,967 |
| FarxigaDapagliflozin Propanediol | 92 | $133,419 |
| JardianceEmpagliflozin | 57 | $70,606 |
| Tresiba Flextouch U-100Insulin Degludec | 89 | $65,141 |
| JanuviaSitagliptin Phosphate | 45 | $54,609 |
| MounjaroTirzepatide | 44 | $49,666 |
| Xigduo XrDapaglifloz Propaned/Metformin | 36 | $40,834 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 23 | $26,331 |
| Novolog FlexpenInsulin Aspart | 123 | $19,318 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $17,127 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $12,775 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $12,735 |
| Levemir FlexpenInsulin Detemir | 49 | $11,241 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $5,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $150 | $70,60657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.